POTASSIUM CHLORIDE Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride

fresenius kabi limited - potassium chloride - concentrate for soln for inf - 15 %w/v - potassium chloride

Potassium Chloride 15% w/v Concentrate for Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 15% w/v concentrate for solution for infusion

mercury pharmaceuticals (ireland) ltd - potassium chloride - concentrate for solution for infusion - 15 percent weight/volume - potassium; potassium chloride

POTASSIUM CHLORIDE IN LACTATED RINGERS AND DEXTROSE- potassium chloride, sodium chloride, calcium chloride, sodium lactate, and United States - English - NLM (National Library of Medicine)

potassium chloride in lactated ringers and dextrose- potassium chloride, sodium chloride, calcium chloride, sodium lactate, and

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need

POTASSIUM CHLORIDE- potassium chloride e-r capsule, coated, extended release United States - English - NLM (National Library of Medicine)

potassium chloride- potassium chloride e-r capsule, coated, extended release

nucare pharmaceuticals,inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 8 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal s

potassium chloride- potassium chloride capsule, extended release United States - English - NLM (National Library of Medicine)

potassium chloride- potassium chloride capsule, extended release

ethex - potassium chloride (unii: 660yq98i10) (potassium ion - unii:295o53k152) - capsule, extended release - 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrhe

POTASSIUM CHLORIDE tablet, film coated, extended release United States - English - NLM (National Library of Medicine)

potassium chloride tablet, film coated, extended release

aidarex pharmaceuticals llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patien

Potassium Chloride 15% w/v concentrate for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 15% w/v concentrate for solution for infusion

noridem enterprises limited - potassium chloride - concentrate for solution for infusion - 15 percent weight/volume - electrolyte solutions; potassium chloride

Potassium Chloride 15% w/v Concentrate for Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 15% w/v concentrate for solution for infusion

b. braun medical limited - potassium chloride - concentrate for solution for infusion - 15 percent weight/volume - electrolyte solutions; potassium chloride

Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.45% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6024) Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.45% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6024)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 4.5 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.9% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6066) Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.9% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6066)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 9 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.